You are here

CAR-T

With CAR-T marketing looming, early study highlights potential of TCR engineering

Endpoints

Fri, 08/18/17 - 12:06 pm

Kite shoots for first CAR-T OK in Europe, staying one step behind Novartis in US race

Endpoints

Mon, 07/31/17 - 09:57 am

axicabtagene ciloleucel

CAR-T Cell Therapy Is Here To Stay

Forbes

Wed, 07/19/17 - 09:40 am

How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals

Investors Business Daily

Fri, 07/14/17 - 08:07 am

Novartis wins unanimous support from FDA panel on groundbreaking CAR-T med

Fierce Pharma

Wed, 07/12/17 - 04:29 pm

advisory panels

D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T

Endpoints

Wed, 07/12/17 - 11:00 am

FDA panel to focus on safety of Novartis gene therapy drug

Yahoo/Reuters

Mon, 07/10/17 - 09:32 am

advisory panels

acute lymphoblastic leukemia

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

Endpoints

Thu, 07/6/17 - 02:35 pm

Oxford BioMedica

Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?

Investors Business Daily

Sun, 07/2/17 - 10:07 am

Juno Therapeutics

immuno-oncology

3 Top-Performing Biotech Stocks This Week

Motley Fool

Fri, 06/16/17 - 09:51 am

Lexicon Pharmaceuticals

With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now

Endpoints

Wed, 06/14/17 - 11:43 am

Juno Therapeutics

Kite Pharma: How High Will It Fly?

Seeking Alpha

Tue, 06/13/17 - 10:33 am

Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment

Bloomberg

Thu, 06/8/17 - 10:24 pm

Novartis' CAR-T stacks up to Kite in lymphoma

BioPharma Dive

Wed, 06/7/17 - 07:04 pm

ASCO17: Juno marks progress with second-gen CAR-T

BioPharma Dive

Tue, 06/6/17 - 12:16 pm

Juno Therapeutics

non-Hodgkin's lymphoma

July 12 FDA panel review looms as a watershed moment in Novartis’ campaign to win an historic new drug OK

Endpoints

Tue, 06/6/17 - 12:13 pm

advisory panels

pediatric B-cell acute lymphoblastic leukemia

ASCO dark horse Nanjing Legend Biotech shines with promising CAR-T data

Fierce Biotech

Tue, 06/6/17 - 10:41 am

Nanjing Legend Biotech

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

Endpoints

Mon, 06/5/17 - 12:10 pm

Multiple Myeloma

Kite Pharma's ASCO ads aim to prep docs on CAR-T ahead of FDA approval

Fierce Pharma

Mon, 06/5/17 - 12:06 pm

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

Endpoints

Tue, 05/30/17 - 11:48 am

PDL-1 inhibitors

NewLink Genetics

Juno Therapeutics

Bristol-Myers Squibb

Pages